SensoLyte® Anti-Rat MOG (1-125) IgG Quantitative ELISA Kit Colorimetric - 1 kit

Check your price
  • Cat.Number : AS-55157
  • Availability :
    In stock
  • Shipping conditions : Ice fees will apply

Alternative choices


Rat MOG recombinant protein (1-125) [Cat# AS-55152] is able to induces autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination. Autoantibody response to rat MOG (1-125) has been observed in induced experimental autoimmune encephalomyelitis (EAE) in dark agouti (DA) and Lewis rats, C57/BL6 and SJL mice, and common marmoset.
The SensoLyte® Anti-Rat MOG (1-125) IgG Quantitative ELISA Kit provides a convenient quantitative assay for anti-rat MOG (1-125) autoantibody. This colorimetric assay is useful to researchers for determining the amount of anti-rat MOG (1-125) antibody present, and can help provide information on the role it plays in the development and treatment of EAE, an animal model for multiple sclerosis pathogenesis.


Kits components
  • Component A: Rat-MOG (1-125) coated and BSA blocked 8-well strips: 12 strips Component B: Anti-Rat MOG (1-125) IgG standard: 100 µl (20 µg/ml) Component C: 1X Sample Dilution Buffer: 30 ml Component D: 10X Wash Buffer: 50 ml Component E: TMB color substrate solution: 10 ml Component F: Stop Solution: 10 ml Component G Secondary antibody, Goat anti-Rat IgG-HRP: 30 µl
UniProt number
  • Q63345
Storage & stability
Storage Conditions
  • Store all other components at 4°C for up to 6 months. Store component B at -20°C in small aliquots. Protect components E and G from light.
Biomarker Target
Detection Method
Detection Limit
  • 1 ng/ml
Research Area
Sub-category Research Area
  • Research use

You may also be interested in the following product(s)


MOG (35-55), mouse, rat

Cat.Number : AS-60130-1
$182.00 Excl. Tax

Recombinant rat MOG (1-125)

Cat.Number : AS-55152-100
$249.00 Excl. Tax


Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone

Behav Brain Res. . 2021 Jan 01 ; 396 112896 | DOI : 10.1016/j.bbr.2020.112896

  • AJ. Kwilasz
  • et al